Home › Funds › BVF INC/IL › CGEM
BVF INC/IL position in CGEM
CULLINAN THERAPEUTICS INC · Health Care
BVF INC/IL reported holding 5,750,683 shares of CGEM (CULLINAN THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$104.7M, representing 2.68% of its reported portfolio and ranking #12 among its reported holdings. BVF INC/IL has disclosed CGEM holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How BVF INC/IL's CGEM position evolved
BVF INC/IL first disclosed a stake in CGEM in Q3 2023 at 3,196,701 shares (US$28.9M). The position peaked in Q2 2026 at 5,750,683 shares, worth US$104.7M. Across 12 filings, BVF INC/IL increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 10 time(s). The most recent filing (Q2 2026) shows 5,750,683 shares valued at US$104.7M. Notable position changes include a 80% increase in Q2 2024 (shares fell 4% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 3.20M | $28.93M | New |
| Q4 2023 | 3.20M | $32.57M | Hold |
| Q1 2024 | 3.20M | $54.47M | Hold |
| Q2 2024 | 5.75M | $100.29M | Add |
| Q3 2024 | 5.75M | $96.27M | Hold |
| Q4 2024 | 5.75M | $70.04M | Hold |
| Q1 2025 | 5.75M | $43.53M | Hold |
| Q2 2025 | 5.75M | $43.30M | Hold |
| Q3 2025 | 5.75M | $34.10M | Hold |
| Q4 2025 | 5.75M | $59.52M | Hold |
| Q1 2026 | 5.75M | $81.72M | Hold |
| Q2 2026 | 5.75M | $104.72M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CGEM and 13F data
CGEM (CULLINAN THERAPEUTICS INC) is a Health Care company. 37 other funds we track also report a position in CGEM — the largest reported positions include MPM BioImpact LLC (US$177.2M), Lynx1 Capital Management LP (US$163.2M), Kynam Capital Management, LP (US$56.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CGEM
- MPM BioImpact LLC 9.73M sh · $177.21M · Q2 2026
- Lynx1 Capital Management LP 8.96M sh · $163.23M · Q2 2026
- Kynam Capital Management, LP 3.11M sh · $56.71M · Q2 2026
- RTW INVESTMENTS, LP 2.36M sh · $43.05M · Q2 2026
- Siren, L.L.C. 1.89M sh · $34.48M · Q2 2026
- Blue Owl Capital Holdings LP 1.54M sh · $28.04M · Q2 2026
- Venrock Adviser, LLC 1.38M sh · $25.13M · Q2 2026
- BOOTHBAY FUND MANAGEMENT, LLC 1.08M sh · $19.71M · Q2 2026
- Affinity Asset Advisors, LLC 875.76K sh · $15.95M · Q2 2026
- BOONE CAPITAL MANAGEMENT LLC 704.44K sh · $12.83M · Q2 2026
- Elmind Capital, LP 690.00K sh · $12.56M · Q2 2026
- TWIN FOCUS CAPITAL PARTNERS, LLC 595.49K sh · $10.84M · Q2 2026
FAQ
How long has BVF INC/IL held CGEM?
BVF INC/IL has disclosed CGEM holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is BVF INC/IL's current position in CGEM?
As of Q2 2026, BVF INC/IL holds 5.75M shares of CGEM (CULLINAN THERAPEUTICS INC), valued at $104.72M, representing 2.68% of its reported portfolio and ranking #12.
Has BVF INC/IL been buying or selling CGEM?
In the latest 13F filing (Q2 2026), BVF INC/IL held unchanged its position in CGEM. The position peaked in Q2 2026 at 5.75M shares.
Which other funds hold CGEM?
Other major institutional holders of CGEM include MPM BioImpact LLC, Lynx1 Capital Management LP, Kynam Capital Management, LP, among 37 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.